CRBU News and Press, Caribou Biosciences Inc.

2026-03-05 16:37:35 ET More on Caribou Bioscience Caribou Biosciences, Inc. (CRBU) Presents at 2026 Tandem Meetings of ASTCT and CIBMTR - Slideshow Caribou Biosciences a new buy at Clear Street on CAR-T pipeline Seeking Alpha’s Quant Rating on Caribou Bioscien...

BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences , Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights...

Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data demonstrate efficacy and durability that is on par with autologous CAR-T cell therapy in 2L ...

2026-02-03 12:27:04 ET More on Caribou Biosciences Caribou Biosciences, Inc. (CRBU) Presents at Evercore 8th Annual Healthcare Conference Transcript Caribou Bioscience GAAP EPS of -$0.30 beats by $0.07, revenue of $2.2M misses by $0.07M Seeking Alpha’s Quant R...

VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034 [1] , driven by a fundamental shift in how physicians combat cancer's most resistant forms. ...

KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting BERKELEY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CR...

2025-11-13 00:29:44 ET More on Caribou Bioscience Caribou Biosciences: A Much Anticipated Data Readout Does Not Quite Get My Buy Seeking Alpha’s Quant Rating on Caribou Bioscience Historical earnings data for Caribou Bioscience Financial information fo...

Vispa-cel (CB-010) ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for outpatient use, highlighting its potential as a best-in-class allogeneic CAR-T cell therapy for LBCL CB-011 CaMMouflage phase 1 data demonstrate dee...

RWE AG ADR (RWEOY) is expected to report $0.16 for Q3 2025 Hillenbrand Inc (HI) is expected to report $0.62 for Q4 2025 Ardent Health Inc. (ARDT) is expected to report $0.42 for Q3 2025 Quince Therapeutics Inc. (QNCX) is expected to report $-0.2 for Q3 2025 GlobalFoundries Inc. (G...

Curaleaf Holdings Inc (CURLF) is expected to report $-0.07 for Q3 2025 Southwest Gas Holdings Inc. (DE) (SWX) is expected to report $0.09 for Q3 2025 Terreno Realty Corporation (TRNO) is expected to report $0.65 for Q3 2025 Bio-Techne Corp (TECH) is expected to report $0.36 for Q1 202...